Skip to content
OpenCapital
Get started

TuHURA Biosciences, Inc. HURA Finance Lease, Principal Payments

Finance Lease, Principal Payments at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
——

Other financials

Income statement

See full
Revenue-—
Net income-$7.5M-13.1%
EPS (diluted)-$0.13+13.3%

Balance sheet

See full
Cash & equivalents$6.3M+1.3%
Total debt$456.9K+178%
Total equity$23.2M+135%
Total assets$29.7M+103%

Cash flow

See full
Operating cash flow-$4.4M+6.9%
CapEx$48.8K+14.5%
Free cash flow-$4.5M+6.7%

Valuation

See full
Market cap$155.39M+45.8%
Enterprise value$149.54M+52.3%

Returns & leverage

See full
Return on equity-187.2%—
Debt / equity0×0.0×
Current ratio1.2×-1.8×

Where this comes from

Reported directly by TuHURA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeasePrincipalPayments.

The official record: TuHURA Biosciences, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about TuHURA Biosciences, Inc.'s finance lease, principal payments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TuHURA Biosciences, Inc.'s finance lease, principal payments?
TuHURA Biosciences, Inc. (HURA) reported finance lease, principal payments of $10.85K in Q1 2026.